Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;91(3):999-1006.
doi: 10.3233/JAD-220886.

Handgrip Strength Is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden

Somayeh Meysami  1   2 , Cyrus A Raji  3 , Ryan M Glatt  1   4 , Emily S Popa  1 , Aarthi S Ganapathi  1 , Tess Bookheimer  1 , Colby B Slyapich  1 , Kyron P Pierce  1 , Casey J Richards  1 , Melanie G Lampa  1 , Jaya M Gill  1 , Molly K Rapozo  1 , John F Hodes  1   5 , Ynez M Tongson  4 , Claudia L Wong  1   4 , Mihae Kim  1   4 , Verna R Porter  1   2   4 , Scott A Kaiser  1   4 , Stella E Panos  1   2   4 , Richelin V Dye  1   6 , Karen J Miller  1   2   7 , Susan Y Bookheimer  1   7 , Neil A Martin  1   2   4 , Santosh Kesari  1   2   4 , Daniel F Kelly  1   2   4 , Jennifer E Bramen  1   2   4 , Prabha Siddarth  1   7 , David A Merrill  1   2   4   7
Affiliations

Handgrip Strength Is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden

Somayeh Meysami et al. J Alzheimers Dis. 2023.

Abstract

Background: Strength and mobility are essential for activities of daily living. With aging, weaker handgrip strength, mobility, and asymmetry predict poorer cognition. We therefore sought to quantify the relationship between handgrip metrics and volumes quantified on brain magnetic resonance imaging (MRI).

Objective: To model the relationships between handgrip strength, mobility, and MRI volumetry.

Methods: We selected 38 participants with Alzheimer's disease dementia: biomarker evidence of amyloidosis and impaired cognition. Handgrip strength on dominant and non-dominant hands was measured with a hand dynamometer. Handgrip asymmetry was calculated. Two-minute walk test (2MWT) mobility evaluation was combined with handgrip strength to identify non-frail versus frail persons. Brain MRI volumes were quantified with Neuroreader. Multiple regression adjusting for age, sex, education, handedness, body mass index, and head size modeled handgrip strength, asymmetry and 2MWT with brain volumes. We modeled non-frail versus frail status relationships with brain structures by analysis of covariance.

Results: Higher non-dominant handgrip strength was associated with larger volumes in the hippocampus (p = 0.02). Dominant handgrip strength was related to higher frontal lobe volumes (p = 0.02). Higher 2MWT scores were associated with larger hippocampal (p = 0.04), frontal (p = 0.01), temporal (p = 0.03), parietal (p = 0.009), and occipital lobe (p = 0.005) volumes. Frailty was associated with reduced frontal, temporal, and parietal lobe volumes.

Conclusion: Greater handgrip strength and mobility were related to larger hippocampal and lobar brain volumes. Interventions focused on improving handgrip strength and mobility may seek to include quantified brain volumes on MR imaging as endpoints.

Keywords: Brain volumes; handgrip; mobility; prevention.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/22-0886r1).

References

    1. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362, 329–344. - PubMed
    1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N (2020) Dementiaprevention, intervention, and care: 2020 report of the LancetCommission. Lancet 396, 413–446. - PMC - PubMed
    1. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 10, 819–828. - PMC - PubMed
    1. Argueta N, Notari E, Szigeti K (2022) Role of pharmacogenomics in individualizing treatment for Alzheimer’s disease. CNS Drugs 36, 365–376. - PubMed
    1. Hodes JF, Oakley CI, O’Keefe JH, Lu P, Galvin JE, Saif N, Bellara S, Rahman A, Kaufman Y, Hristov H, Rajji TK, Fosnacht Morgan AM, Patel S, Merrill DA, Kaiser S, Meléndez-Cabrero J, Melendez JA, Krikorian R, Isaacson RS (2019) Alzheimer’s “Prevention” vs.“Risk Reduction”: Transcending Semantics for Clinical Practice. Front Neurol 9, 1179. - PMC - PubMed

Publication types